Clinical Trial Update: Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating the combination of trastuzumab deruxtecan (DS-8201a) and azenosertib (ZN-c3) in gastric and gastroesophageal junction cancers …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Azenosertib (ZN-c3) (azenosertib)
• Enhertu (trastuzumab deruxtecan)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Phase 1 | Status: RECRUITING